List of Excipients in Branded Drug THEOPHYLLINE IN DEXTROSE

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
B Braun Medical Inc	THEOPHYLLINE IN DEXTROSE	theophylline anhydrous and dextrose	0264-9554	WATER

Theophylline in Dextrose: Excipient Strategy, Patent Position, and Commercial Opportunities

Last updated: August 28, 2026

Theophylline in dextrose is a mature sterile injectable product with limited patent protection and modest technical differentiation. Its commercial value depends on manufacturing reliability, hospital procurement, ready-to-use presentation, supply continuity, and control of excipient-related risks rather than on active-ingredient exclusivity. A practical product strategy is a preservative-free, terminally sterilized or aseptically filled dextrose premix in multiple strengths, supported by strong stability data and a low-complexity hospital supply chain.

What is the formulation of theophylline in dextrose injection?

Theophylline in dextrose injection combines the bronchodilator theophylline with a dextrose solution for intravenous administration. Public labeling describes products in 5% dextrose, commonly supplied in 400 mg/500 mL and 800 mg/500 mL presentations, equivalent to approximately 0.8 mg/mL and 1.6 mg/mL of theophylline, respectively.[1]

Formulation element	Commercial function	Key development issue
Theophylline	Active pharmaceutical ingredient	Narrow therapeutic index and dose-related toxicity
Dextrose, commonly 5%	Vehicle and carbohydrate source	Osmolality, degradation, container compatibility
Water for Injection	Sterile solvent	Microbial and endotoxin control
pH adjusters, where used	Solubility and stability control	Local tolerability and precipitation risk
Container-closure system	Sterility and shelf-life protection	Extractables, leachables, oxygen and moisture transmission

Theophylline has limited aqueous solubility compared with many conventional injectable drugs. Formulation pH, concentration, temperature, and salt form affect precipitation risk. The product must remain clear and free of visible particulate matter throughout storage and administration.

The narrow therapeutic index creates a second formulation constraint. The product must support accurate dosing and avoid concentration variability caused by precipitation, adsorption, evaporation, or container interaction. The FDA label warns that theophylline toxicity is associated with elevated serum concentrations and that dosing requires clinical monitoring.[1]

What excipients are used in theophylline in dextrose products?

The core excipient platform is simple: dextrose in Water for Injection, with pH adjustment when required. Public product labels should control the definitive inactive-ingredient composition for a particular manufacturer and strength.[1]

Dextrose concentration and vehicle selection

Dextrose 5% is commercially attractive because it is familiar to hospitals and aligns with established intravenous-fluid infrastructure. It provides a mildly hypertonic solution and avoids the need to introduce a more complex solubilizing system.

Potential alternatives include:

• Lower or higher dextrose concentrations, subject to osmolality and labeling requirements.
• Sodium chloride-based vehicles, where clinically and commercially appropriate.
• Dextrose-saline combinations for specific institutional protocols.
• Concentrated presentations intended for dilution before administration.

A dextrose vehicle can create development and packaging issues. Reducing sugars may participate in degradation pathways with susceptible drug molecules or excipients. The manufacturer should evaluate color formation, assay loss, impurity growth, pH drift, and container interaction under accelerated and long-term conditions.

pH adjustment

The formulation should use the minimum pH-adjustment system necessary to achieve solubility and stability. Excessive acid or base can increase local tolerability concerns and create a formulation that is more vulnerable to pH drift during storage.

The development package should include:

• pH range at release and expiry.
• Theophylline assay and related substances.
• Visible and subvisible particulate matter.
• Precipitation after refrigeration, freezing excursion, and rewarming.
• Compatibility with common infusion sets and secondary containers.
• Stability after opening or transfer, if the labeling permits those uses.

Preservatives and antimicrobial systems

A preservative-free presentation is generally the stronger hospital product strategy for an intravenous premix. Preservatives may create safety and compatibility concerns, particularly in neonates, critically ill patients, or patients receiving multiple parenteral products. A single-use container with validated sterility controls can remove the need for antimicrobial preservatives.

The commercial benefit is a simpler label and broader institutional acceptance. The tradeoff is a higher burden on aseptic processing, container closure integrity, and microbial control.

What patent protection covers theophylline in dextrose?

Theophylline in dextrose is unlikely to have meaningful remaining composition-of-matter patent protection. Theophylline is an old active pharmaceutical ingredient, and conventional dextrose premix formulations are generally vulnerable to development by multiple generic manufacturers.

IP category	Likely position for theophylline in dextrose	Commercial impact
Theophylline composition of matter	Expired or commercially irrelevant due to age of molecule	No active-molecule barrier
Conventional dextrose solution	Low patentability	Limited blocking potential
Standard intravenous premix	Usually low differentiation	Generic competition likely
Stability-enhanced formulation	Potentially protectable if technically non-obvious	Narrower but more defensible
Container or administration system	Potentially protectable	Protection depends on claim scope
Manufacturing process	Potentially protectable as trade secret or patent	May delay replication but rarely blocks all entry
Method of treatment	Possible only for specific, non-obvious clinical use	Limited value for established indications

A complete freedom-to-operate analysis would require a live patent search across the specific formulation, container, manufacturing process, and intended market. No patent number, assignee, or expiry date should be attributed to a generic theophylline-in-dextrose product without a product-specific search.

When does theophylline in dextrose lose exclusivity?

The product has no evident commercial value from new-drug exclusivity. Theophylline has been marketed for decades, and conventional injectable presentations are generally treated as mature generic products. The principal barriers are abbreviated-approval requirements, sterile manufacturing capability, product-specific bioequivalence or clinical requirements, and supply qualification.

The FDA Orange Book identifies approved drug products and certain patents or exclusivity statements associated with listed products. It does not create exclusivity for every formulation or automatically confirm that a specific generic premix has no patent risk.[2]

Orange Book status

For a conventional theophylline-in-dextrose injection:

• The product is expected to compete primarily as a prescription generic or legacy injectable.
• No biologic exclusivity framework applies.
• Biosimilar approval is irrelevant because theophylline is a small molecule.
• Paragraph IV litigation is not a central expected risk for an old, conventional premix unless an active listed patent is attached to a particular reference product.
• Any patent listing must be checked against the exact reference product, dosage form, strength, and sponsor.

Are Paragraph IV challenges likely for theophylline in dextrose?

Paragraph IV risk is likely to be limited because the commercial product concept is old and the market is not typically dominated by a recently approved branded reference product. A Paragraph IV certification becomes commercially relevant only if a listed patent covers the applicable reference product.

Potential challenges could target:

• A listed formulation patent.
• A concentration-specific claim.
• A container-closure or premix configuration.
• A method-of-use patent linked to a particular clinical indication.
• A manufacturing claim that is listed or otherwise asserted in litigation.

For a conventional 5% dextrose product, a generic entrant would more likely rely on the absence of enforceable patents, Paragraph III certification where applicable, or a non-infringing formulation design than on complex litigation strategy.

What formulations are protected by the strongest intellectual property?

The most defensible IP would come from a measurable technical improvement rather than from the basic combination of theophylline and dextrose.

Potential formulation patent opportunities

Candidate areas include:

1. A high-concentration theophylline solution with demonstrated resistance to precipitation across clinically relevant temperature excursions.
2. A low-impurity formulation that reduces degradation in the presence of dextrose.
3. A container system that materially reduces adsorption, leachables, oxygen exposure, or drug loss.
4. A ready-to-use product with extended in-use stability after connection to an infusion set.
5. A formulation that eliminates a problematic excipient while preserving solubility and shelf life.
6. A dual-chamber or compartmentalized system that separates theophylline from dextrose until administration.

These concepts would face substantial obviousness risk. A patent application would need comparative data showing an unexpected result, such as superior stability, lower particulate formation, improved recovery after thermal stress, or a clinically meaningful administration advantage.

Trade-secret opportunities

Manufacturing know-how may have more practical value than patents. Relevant know-how includes:

• Order of addition.
• Mixing temperature and time.
• Control of dissolved oxygen.
• Filtration conditions.
• Hold times before filling.
• Sterilization cycle parameters.
• Container-closure preparation.
• Release specifications for color, particles, pH, and assay.

Trade-secret protection can delay replication but does not prevent an independent manufacturer from developing a comparable process.

What commercial opportunities exist for theophylline in dextrose?

The strongest opportunity is a reliable hospital product rather than a premium branded drug.

Ready-to-use hospital premix

Hospitals may prefer a premixed, labeled infusion product over pharmacy compounding when the product reduces preparation time, medication-error risk, and waste. A ready-to-use bag can compete on:

• Consistent concentration.
• Clear administration instructions.
• Reduced manipulation.
• Lower compounding labor.
• Reliable stock availability.
• Simple barcode and inventory integration.

Supply-shortage positioning

Sterile injectables are vulnerable to manufacturing interruptions, raw-material constraints, and quality-related shortages. A new supplier can gain share through dual manufacturing sites, validated alternate suppliers, and a differentiated container portfolio.

The product should be positioned around continuity of supply, not therapeutic novelty. A hospital buyer is more likely to value predictable delivery and low defect rates than a minor change in excipient composition.

Strength and package-size expansion

Commercial options include:

Product option	Opportunity
400 mg/500 mL	Lower-strength standard premix
800 mg/500 mL	Higher-strength premix with reduced fluid volume
Smaller-volume bag	Useful where fluid restriction matters
Single-dose container	Reduces manipulation and contamination risk
Pharmacy bulk package	May support institutional compounding, subject to regulatory requirements
Concentrate for dilution	Lower shipping volume but higher preparation burden

Any higher-strength product must address solubility, osmolality, dosing accuracy, and administration instructions. Reduced fluid volume can be commercially useful but may narrow the acceptable patient population.

How does theophylline in dextrose compare with competing bronchodilator products?

Theophylline competes with inhaled beta-agonists, anticholinergic agents, systemic corticosteroids, and other respiratory therapies. Its main disadvantage is the narrow therapeutic index and need for serum-level monitoring. Its potential advantages are low active-ingredient cost, established clinical familiarity, and availability as an intravenous formulation.

Competitive factor	Theophylline in dextrose	Modern inhaled bronchodilators
Administration	Intravenous	Inhaled
Monitoring	Serum-level monitoring may be required	Usually less intensive for routine dosing
Formulation complexity	Sterile solution and precipitation control	Device and aerosol-performance control
Patent exposure	Generally low for old generic product	Can be substantial for branded inhalers and devices
Hospital value	Rescue or selected inpatient use	Broad outpatient and inpatient use
Differentiation	Packaging, stability, supply	Device, formulation, duration, clinical profile

The product is more likely to occupy a niche in hospital formularies than to regain broad outpatient market share.

What manufacturing and regulatory barriers affect market entry?

Sterile injectable production is the main barrier. The product requires validated facilities, environmental controls, aseptic processing or terminal sterilization where feasible, container-closure integrity, particulate controls, and stability data.

Key regulatory workstreams include:

• Compliance with FDA current good manufacturing practice requirements.
• Drug product quality testing under applicable USP standards.
• Sterility, bacterial endotoxin, particulate, and container-closure testing.
• Extractables and leachables evaluation.
• Compatibility studies with administration systems.
• Labeling that reflects concentration, dosing, warnings, and storage.
• An abbreviated or legacy regulatory pathway appropriate to the specific product and reference listing.[2,3]

Dextrose products also require control of visible color and degradation products. The manufacturing process should be designed to minimize heat exposure and avoid unnecessary oxygen ingress.

What litigation and settlement risks affect the product?

No major litigation or settlement can be assigned to the product category without identifying a specific sponsor, reference product, patent, or court proceeding. The expected litigation profile is lower than for recently approved specialty drugs, long-acting injectables, or complex inhaled products.

Potential disputes would most likely involve:

• A formulation patent covering a stability-enhanced product.
• A container or delivery-system patent.
• ANDA certification language.
• Manufacturing-process claims.
• Product liability associated with dosing errors, particulates, or contamination.
• Contract-manufacturing or supply agreements.

A company entering this market should prioritize freedom-to-operate review and regulatory comparability over litigation budgeting.

How strong is the patent estate for theophylline in dextrose?

The conventional product estate is weak. The active ingredient is old, the vehicle is conventional, and the clinical use is established. Patent strength improves only when the sponsor can document a specific technical advance.

A practical scoring framework is:

IP asset	Expected strength
Theophylline plus standard 5% dextrose	Low
New concentration without unexpected performance	Low
Improved stability with comparative evidence	Moderate
Novel container with measured drug-preservation benefit	Moderate
Integrated delivery system with non-obvious functionality	Moderate to potentially strong
Manufacturing process alone	Variable, often difficult to enforce

Commercial protection is therefore more likely to come from scale, quality history, hospital contracts, shortage response, and reliable manufacturing than from exclusionary patent rights.

Key Takeaways

• Theophylline in dextrose is a mature sterile injectable opportunity with limited active-ingredient exclusivity.
• A preservative-free, ready-to-use 5% dextrose premix is the most practical baseline product.
• The main formulation risks are solubility, precipitation, pH drift, dextrose-related degradation, particulates, and container compatibility.
• A conventional product is unlikely to support a strong patent estate without comparative stability or delivery-system data.
• Paragraph IV and biosimilar risks are limited relative to newer small-molecule and biologic products.
• Commercial differentiation should focus on supply reliability, multiple strengths, packaging, hospital workflow, and shortage resilience.
• Manufacturing capability and regulatory execution are more important barriers than composition-of-matter patents.
• The strongest IP opportunity lies in stability-enhanced formulations, novel containers, administration systems, or compartmentalized products with measurable technical advantages.

FAQs

Is theophylline in dextrose a biologic or biosimilar product?

No. Theophylline is a small-molecule drug. Biosimilar approval and biologic exclusivity rules do not apply.

Can a manufacturer patent a 5% dextrose theophylline injection?

A basic combination of theophylline and 5% dextrose would face substantial novelty and obviousness challenges. Patentability would be stronger if the formulation produced an unexpected stability, solubility, packaging, or administration result.

What is the main clinical risk in commercializing injectable theophylline?

The principal risk is dose-related toxicity caused by theophylline's narrow therapeutic index. Product labeling, concentration control, dosing instructions, and hospital-use safeguards are central commercial requirements.[1]

Is a concentrated theophylline premix commercially attractive?

It may be attractive where reduced fluid volume has value, but the product must demonstrate acceptable solubility, stability, osmolality, administration compatibility, and dosing practicality.

What is the best competitive advantage for a new supplier?

Reliable sterile manufacturing and uninterrupted hospital supply are likely to create more value than a minor excipient change. A strong product would combine validated stability, preservative-free packaging, barcode-ready labeling, multiple strengths, and redundant supply capacity.

References

1. DailyMed. (n.d.). Theophylline in dextrose injection, USP: Prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

3. U.S. Food and Drug Administration. (2015). Guidance for industry: ANDAs for certain highly purified synthetic peptides. https://www.fda.gov/regulatory-information/search-fda-guidance-documents

4. United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.